In the meeting, the FDA and Mereo agreed in principle on an outline for the design of a Phase Three clinical trial programme to support the development of acumapimod as a five day treatment ...

No new safety findings have been observed with continued blarcamesine treatment over three (3) years with good ... Investigator for the blarcamesine Phase IIb/III ANAVEX ® 2-73-AD-004 study.

In two of three phase 3 trials ... use of a permuted-block design, and the study drug was assigned by means of an interactive voice-response system. Concomitant treatment with any investigational ...

Amylyx to present the Phase 3 LUCIDITY trial design at the World ... The trial will include a three-week run-in period and a 16-week double-blind treatment period. Participants who complete ...

In preclinical and phase 1 ... who had treatment-resistant hypertension, with blood pressure of 130/80 mm Hg or higher, and who were receiving stable doses of at least three antihypertensive ...

Aura Biosciences announced that it has received an agreement from the FDA under a special protocol assessment for the design of a phase 3 trial ... for bel-sar for the treatment of early-stage ...

DUBLIN, April 1, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical ... development as a once-daily treatment for narcolepsy type ...